- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02639299
조사용 항말라리아제, 말라리아 백신 및 통제된 인간 말라리아 챌린지를 위한 건강한 지원자 선별
Background:
Malaria is a serious infection caused by a parasite. People get malaria when an infected mosquito bites them. Malaria can cause major health and social problems in places were malaria is common, such as Africa but can also affect travelers who have never been exposed to malaria. Researchers at the NIH want to find a safe and effective malaria vaccine, antimalarial drugs, or prevention regimen. To do this, healthy volunteers are recruited under a general screening study in order to see if are qualified to join a future malaria study.
Objective:
To screen healthy volunteers to see if they are eligible to join investigational malaria studies. The studies will be trials of investigational antimalarial drugs, malaria vaccines, or prevention regimens. They may also involve controlled human malaria infection trials.
Eligibility:
Healthy people ages 18 50
Design:
Participants will first be prescreened by phone.
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Participants may go more than 1 year without joining a clinical trial. If this happens, they may be re-contacted to see if they still want to be part of this screening protocol. Those who still want to participate and have had relevant medical changes will be rescreened.
연구 개요
상태
정황
상세 설명
This is a screening protocol for healthy volunteers to participate in research studies conducted by Laboratory of Malaria Immunology and Vaccinology (LMIV).
Malaria-related morbidity and mortality have a major economic impact in endemic regions and
present a substantial health risk to non-immune travelers and people living in endemic areas. To stem the worldwide impact of this devastating disease, a safe and broadly effective malaria vaccine and improved antimalarial therapeutics are urgently required.
This screening protocol is designed to continuously evaluate potential healthy volunteers to build a pool of volunteers who may participate in future and ongoing LMIV malaria drug, vaccine, or controlled human malaria infections (CHMI) trials. A complete medical history and blood and urine samples will be obtained to evaluate whether volunteers are eligible for study-specific screening.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: David M Cook, M.D.
- 전화번호: (240) 627-3066
- 이메일: cookdm@mail.nih.gov
연구 장소
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- 모병
- National Institutes of Health Clinical Center
-
연락하다:
- For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
- 전화번호: 888-624-1937
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
healthy volunteers in the Washington, DC region
설명
- INCLUSION CRITERIA:
All of the following criteria must be fulfilled for a subject to participate in this trial:
- Age >= 18 and <= 50 years.
- In good general health and without clinically significant medical history
- Reliable access to the clinical trial center and available in the area for more than 1 year
- Females of childbearing potential must be willing to undergo periodic pregnancy testing and use reliable contraception per protocol when enrolled into LMIV clinical trials (protocol-specific requirements)
EXCLUSION CRITERIA:
A subject will be excluded from participating in this trial if any one of the following criteria is fulfilled:
-
Pregnant, breastfeeding, or planned pregnancy in the upcoming year.
-
Hemoglobin, white blood cell (WBC), platelets, alanine transaminase (ALT), and creatinine (Cr) outside of local lab normal range (subjects may be included at the investigator's discretion for "not clinically significant" values outside of normal range).
-
Anticipated use during the study period, or use within the following periods prior to enrollment:
- Investigational malaria vaccine within the last five years
- Chronic systemic immunosuppressive medications (e.g., cytotoxic medications, oral/parental corticosteroids > 0.5 mg/kg/day prednisone or equivalent). Corticosteroid nasal spray for allergic rhinitis and topical corticosteroids for mild, uncomplicated dermatitis is allowed.
- Recurrent receipt of blood products or immunoglobulins
-
History of:
- Sickle cell disease
- Splenectomy or functional asplenia
- Systemic anaphylaxis
- Uncontrolled psoriasis or porphyria
-
Clinically significant medical condition, physical examination findings, other clinically significant abnormal laboratory results, or past medical history that may have clinically significant implications for current health status and participation in the study in the opinion of the Investigator. A clinically significant condition or process includes but is not limited to:
- A process that would affect the immune response, or requires medication that affects the immune response.
- Any contraindication to repeated phlebotomy.
-
History of or known active cardiac disease including:
- prior myocardial infarction (heart attack)
- angina pectoris
- congestive heart failure
- valvular heart disease
- cardiomyopathy
- pericarditis
- stroke or transient ischemic attack
- exertional chest pain or shortness of breath
- other heart conditions under the care of a doctor
-
Infection with HIV, hepatitis B, and/or hepatitis C
-
Psychiatric condition that precludes compliance with the protocol including but not limited to:
- Psychosis within the past 3 years
- Ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years
-
Suspected or known current alcohol or drug abuse as defined by the American Psychiatric Association in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the discretion of the PI
-
Any other finding that, in the judgment of the Investigator, would interfere with, or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a subject's ability to give informed consent, or increase the risk of having an adverse outcome from participating in the study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: OTHER
- 시간 관점: CROSS_SECTIONAL
코호트 및 개입
그룹/코호트 |
|---|
|
Healthy volunteer
healthy, malaria-na(SqrRoot) ve US adults |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To screen healthy volunteers for future malaria studies
기간: 1 year
|
identify healthy adults at a low risk of developing complications due to experimental malaria infection, investigational antimalarials and vaccines |
1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: David M Cook, M.D., National Institute of Allergy and Infectious Diseases (NIAID)
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 160039
- 16-I-0039
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
This is a screening protocol for healthy volunteers to participate in research studies conducted by Laboratory of Malaria Immunology and Vaccinology (LMIV).@@@@@@@@@@@@This screening protocol is designed to evaluate potential healthy volunteers to build a pool of volunteers who may participate in future and ongoing LMIV malaria drug, vaccine, or controlled human malaria infections (CHMI) trials. Data obtained for individual subjects will used not be used for direct research purposes on this study; therefore we will not make IPD available at this time.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .